Six Points of Miscommunication Between Oncologists and Pathologists

Slideshow

Regardless of where you practice, good communication between you and your pathologist is the best way to ensure that correct testing is done. Here are six common points of miscommunication to watch out for.

References:

1. Janne PA. What Are We Talking About: Next-Generation Sequencing, Sanger Sequencing, etc. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

2. Aisner D. Tissue is the Issue: The Pathologist’s Role in Facilitating Molecular Analysis. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

3. Nowak JA. The Practitioner's Guide to Using Molecular Testing. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
Related Content
Results from a phase 2a trial showed a 6-month OS and PFS rate of 94% and 72% compared with 67% and 44% from the phase 3 MPACT trial in the first-line treatment of PDAC.

Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC

Tim Cortese
June 17th 2025
Article

Results from a phase 2a trial showed a 6-month OS and PFS rate of 94% and 72% compared with 67% and 44% from the phase 3 MPACT trial in the first-line treatment of PDAC.

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

Real-World Axicabtagene Ciloleucel Shows Consistent Efficacy, Safety in R/R LBCL

Courtney Flaherty
June 17th 2025
Article

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early anti-tumor activity of CID-078 in advanced solid tumors.

CID-078 Earns FDA Orphan Drug Designation in Small Cell Lung Cancer

Roman Fabbricatore
June 17th 2025
Article

Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early anti-tumor activity of CID-078 in advanced solid tumors.

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Jax DiEugenio
June 17th 2025
Article

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.